Logo image of SLDB

SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis

NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD

4.31  +0.66 (+18.08%)

After market: 4.31 0 (0%)

Fundamental Rating

2

Overall SLDB gets a fundamental rating of 2 out of 10. We evaluated SLDB against 567 industry peers in the Biotechnology industry. The financial health of SLDB is average, but there are quite some concerns on its profitability. SLDB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year SLDB has reported negative net income.
SLDB had a negative operating cash flow in the past year.
In the past 5 years SLDB always reported negative net income.
In the past 5 years SLDB always reported negative operating cash flow.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

SLDB's Return On Assets of -39.26% is in line compared to the rest of the industry. SLDB outperforms 56.54% of its industry peers.
SLDB has a Return On Equity of -46.93%. This is in the better half of the industry: SLDB outperforms 66.25% of its industry peers.
Industry RankSector Rank
ROA -39.26%
ROE -46.93%
ROIC N/A
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

1.3 Margins

SLDB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800 -1K

More info and screens

5

2. Health

2.1 Basic Checks

SLDB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SLDB has been increased compared to 1 year ago.
The number of shares outstanding for SLDB has been increased compared to 5 years ago.
Compared to 1 year ago, SLDB has an improved debt to assets ratio.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

SLDB has an Altman-Z score of -0.27. This is a bad value and indicates that SLDB is not financially healthy and even has some risk of bankruptcy.
SLDB has a better Altman-Z score (-0.27) than 62.90% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that SLDB is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.00, SLDB is in line with its industry, outperforming 44.88% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.27
ROIC/WACCN/A
WACC10.04%
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 13.45 indicates that SLDB has no problem at all paying its short term obligations.
The Current ratio of SLDB (13.45) is better than 87.10% of its industry peers.
A Quick Ratio of 13.45 indicates that SLDB has no problem at all paying its short term obligations.
SLDB has a Quick ratio of 13.45. This is amongst the best in the industry. SLDB outperforms 87.10% of its industry peers.
Industry RankSector Rank
Current Ratio 13.45
Quick Ratio 13.45
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

SLDB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.67%, which is quite impressive.
EPS 1Y (TTM)36.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SLDB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.95% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y26.38%
EPS Next 2Y9.99%
EPS Next 3Y7.63%
EPS Next 5Y14.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SLDB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLDB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.99%
EPS Next 3Y7.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLDB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SOLID BIOSCIENCES INC

NASDAQ:SLDB (5/2/2025, 8:23:24 PM)

After market: 4.31 0 (0%)

4.31

+0.66 (+18.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06 2025-03-06/amc
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners73.99%
Inst Owner Change-0.01%
Ins Owners0.97%
Ins Owner Change0.57%
Market Cap334.02M
Analysts85.56
Price Target17.68 (310.21%)
Short Float %12.4%
Short Ratio2.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.9%
Min EPS beat(2)1.9%
Max EPS beat(2)9.9%
EPS beat(4)4
Avg EPS beat(4)6.48%
Min EPS beat(4)0.77%
Max EPS beat(4)13.35%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)2.41%
EPS beat(16)12
Avg EPS beat(16)4.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.69%
PT rev (3m)1.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.73
P/tB 1.73
EV/EBITDA N/A
EPS(TTM)-3.04
EYN/A
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS2.49
TBVpS2.49
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.26%
ROE -46.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-40.77%
ROA(5y)-57.43%
ROE(3y)-50.4%
ROE(5y)-72.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.51%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.45
Quick Ratio 13.45
Altman-Z -0.27
F-Score6
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)75.75%
Cap/Depr(5y)81.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y26.38%
EPS Next 2Y9.99%
EPS Next 3Y7.63%
EPS Next 5Y14.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y8.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.75%
EBIT Next 3Y-18.83%
EBIT Next 5Y5.11%
FCF growth 1Y-2.02%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.67%
OCF growth 3YN/A
OCF growth 5YN/A